B+
Bull case
20%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
WVE
Wave Life SciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
WVE-006 could gain value from a credible accelerated-approval pathway, while WVE-007 data may support differentiated fat loss and body-composition benefits. The stated $490.6 million liquidity and runway into 3Q 2028 provide time to execute without an immediate financing overhang.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -25.6.
What can break
An FDA meeting does not guarantee an accelerated-approval pathway for WVE-006.
Momentum
4
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.25 · Bull $9.00 · Bear $2.75Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $19.94
Why
Momentum4 · Δ7d -0.2
Value41 · Δ7d 0.0
Sentiment75 · Δ7d -25.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -25.6.
Contradictions & invalidation
- • An FDA meeting does not guarantee an accelerated-approval pathway for WVE-006.
- • Clinical development is cash-intensive; the stated runway into 3Q 2028 reduces but does not eliminate future financing and dilution risk. [#SEC-8K-2026-07-30]
- • Regulatory feedback, WVE-007 data, or 2H 2026 study timelines could disappoint or slip.
Catalyst clock
2026-09-30
Post-earnings uncertainty and limited near-term proof points
Lead driver: Sentiment · See AI snapshot
Momentum
4
9% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-4.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
75
62% active weight
Current posture
7d trendSoftening
Δ7d
-25.6
Δ21d
-25.6
Why this grade
Composite grade C. Momentum 3.9 / Value 41.2 / Sentiment 74.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$5.25
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1B
Beta
-1.77
Shares Out
197.05M
P/E (TTM) · Derived
-4.2
P/S (TTM)
25.10
P/FCF (TTM) · Derived
-4.99
Rev YoY
-73.9%
EPS YoY
+10.5%
Gross Margin
+86.0%
Op Margin
-333.4%
Net Debt
-$584.3M
Current Ratio
9.99
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data